MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Travere Therapeutics Inc

Fechado

17.95 2.87

Visão Geral

Variação de preço das ações

24h

Atual

Mín

17.07

Máximo

18.05

Indicadores-chave

By Trading Economics

Rendimento

-5.5M

-60M

Vendas

12M

75M

EPS

-0.47

Margem de lucro

-80.586

Funcionários

385

EBITDA

-4.6M

-45M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+95.93% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-138M

1.7B

Abertura anterior

15.08

Fecho anterior

17.95

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Travere Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de fev. de 2025, 13:58 UTC

Grandes Movimentos do Mercado

Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally

Comparação entre Pares

Variação de preço

Travere Therapeutics Inc Previsão

Preço-alvo

By TipRanks

95.93% parte superior

Previsão para 12 meses

Média 34.17 USD  95.93%

Máximo 47 USD

Mínimo 22 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Travere Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

13

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

17.455 / 20.98Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.